Armor Investment Advisors LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,712 shares of the medical instruments supplier’s stock after purchasing an additional 130 shares during the period. Becton, Dickinson and comprises about 1.7% of Armor Investment Advisors LLC’s investment portfolio, making the stock its 16th biggest holding. Armor Investment Advisors LLC’s holdings in Becton, Dickinson and were worth $1,700,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. BlackRock Inc. increased its holdings in Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after buying an additional 15,887,611 shares during the last quarter. Vanguard Group Inc. raised its stake in Becton, Dickinson and by 5.3% during the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock valued at $2,917,094,000 after buying an additional 796,034 shares in the last quarter. Principal Financial Group Inc. raised its stake in Becton, Dickinson and by 185.3% during the second quarter. Principal Financial Group Inc. now owns 909,235 shares of the medical instruments supplier’s stock valued at $177,401,000 after buying an additional 590,494 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Becton, Dickinson and during the first quarter valued at approximately $101,993,000. Finally, Waverton Investment Management Ltd bought a new position in Becton, Dickinson and during the 2nd quarter worth approximately $68,448,000. 87.12% of the stock is currently owned by institutional investors and hedge funds.

Shares of Becton, Dickinson and Company (BDX) opened at 193.73 on Wednesday. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The stock’s 50 day moving average price is $197.55 and its 200-day moving average price is $192.30. The company has a market cap of $44.09 billion, a PE ratio of 56.10 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.35 earnings per share. On average, equities research analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Friday, September 8th were paid a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.51%. The ex-dividend date was Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 83.43%.

In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the sale, the insider now directly owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The disclosure for this sale can be found here. Insiders sold 75,904 shares of company stock valued at $15,242,688 in the last quarter. 1.40% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Becton, Dickinson and Company (BDX) Shares Bought by Armor Investment Advisors LLC” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/04/becton-dickinson-and-company-bdx-shares-bought-by-armor-investment-advisors-llc.html.

Several brokerages recently issued reports on BDX. Bank of America Corporation restated a “buy” rating and set a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 target price on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a report on Monday, July 17th. Finally, Cowen and Company reissued a “buy” rating and set a $230.00 target price on shares of Becton, Dickinson and in a report on Monday, August 14th. Five investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Becton, Dickinson and presently has an average rating of “Buy” and a consensus price target of $200.93.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.